ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 588

Discovery of Two Public T Cell Receptor Clonotypes in B27+ Ankylosing Spondylitis by Deep Repertoire Sequence Analysis

Malek Faham1, Victoria Carlton2 and Robert D. Inman3, 1Research, Sequenta, Inc., South San Francisco, CA, 2Sequenta, Inc., South San Francisco, CA, 3Dept of Medicine/Rheumatology, Toronto Western Research Institute, University Health Network and University of Toronto, Toronto, ON, Canada

Meeting: 2012 ACR/ARHP Annual Meeting

Keywords: Ankylosing spondylitis (AS) and genomics, T cells

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Title: Spondylarthritis and Psoriatic Arthritis - Pathogenesis, Etiology

Session Type: Abstract Submissions (ACR)

Background/Purpose: The strong association of AS with HLA-B27 implicates a T cell response restricted by this Class I MHC molecule, predicting that specific T Cell Receptor (TCR) sequences would be shared among AS patients.

Methods: We have developed a technology for large scale sequencing of TCR to assess the repertoire profile. All TCR sequences are amplified from peripheral blood and ~1 million TCR sequences are obtained to generate a comprehensive profile of TCR repertoire. We applied this technology to profile B27+ AS (n=128), B27- AS (n=24), B27- mechanical back pain (n=24), healthy controls (n=25) and SLE patients (n=176).

Results: We used a TCR repertoire data from the controls (HC and SLE) to filter out clonotypes present in an appreciable number of these samples. After rigorous control of multiple testing using train and test data sets, two clonotypes were discovered to have significantly different frequencies in B27+ AS population and controls (41% vs 5% and 54% vs19%, p <0.0001).  These clones were further tested in 24 patients with mechanical back pain and 24 B27- AS patients.  The frequency of both clonotypes in the MBP population was similar to that in controls (4% vs 5% and 25% vs 19%).  In B27- AS one clonotype had frequency similar to controls (8% vs 5%), and one had a higher frequency than controls (42% vs. 25% p =0.016). The table below shows the frequency of both clonotypes in the different populations.

Diagnosis         n          Clone 1: no. positive (%)          Clone 2:  no. positive(%)

B27+ AS          128             54 (41%)                                      69 (54%)

B27- AS           24               2 (8%)                                         10 (42%)

MBP                24               1 (4%)                                           6 (25%)

Controls          201             11 (5%)                                        38 (19%)

Conclusion: We provide evidence that there is a distinctive set of shared clonotypes in the T cell repertoire in AS patients. This sheds light on the immunological role of HLA B27 in AS and demonstrates promising specificity for potential diagnostic utility.


Disclosure:

M. Faham,

Sequenta, Inc,

3;

V. Carlton,

Sequenta, Inc,

3;

R. D. Inman,
None.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2012 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/discovery-of-two-public-t-cell-receptor-clonotypes-in-b27-ankylosing-spondylitis-by-deep-repertoire-sequence-analysis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology